Iris Navarro-Millan, MD
RheumatologyAbout Dr. Navarro-Millan
Dr. Navarro-Millan is a rheumatologist with expertise in rheumatoid arthritis. She is a health services, outcomes researcher and implementation scientist. Her background gives her expertise working with different populations and to provide sensitive and compassionate care for her patients. This care is focused on empowering patients to participate in their treatment decision making and overall care.
She is a member of the American College of Rheumatology (ACR) and has served as an ad hoc journal reviewer for: Arthritis & Rheumatism, Journal of Rheumatology, Arthritis Care and Research, Seminars in Arthritis and Rheumatism and Arthritis Research & Therapy.
She is a clinical researcher and her research is directed towards rheumatoid arthritis. She is funded by the NIH and the Rheumatology Research Foundation to conduct studies that focus on implementing treatment guidelines into clinical practices.
Departments
Specialized Centers
Integrative Rheumatology and Orthopedics Center
Procedures
Arthrocentesis
Intra-articular joint injections
Tendon sheath injections
Patient Stories
Insurance
Please call our office if you have questions regarding your insurance coverage. If you have out of network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Credentials
Appointments
Assistant Attending Physician, Hospital for Special Surgery
Assistant Professor, Weill Cornell Medical College
Assistant Professor, NewYork-Presbyterian Hospital
Certification
Board Certified in Rheumatology 2011-2031
Awards
K23 NIH award - NIAMS - Optimization of hyperlipidemia management in patients with rheumatoid arthritis
Innovative Research Award, Rheumatology Research Foundation, 2021
Disease Targeted Innovative Research Award - Rheumatology Research Foundation, 2014
Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center at the University of Alabama at Birmingham (CAMAC) Research Day, First Place, Junior Faculty, 2014
Gene V Ball Award for best case presentation, University of Alabama at Birmingham, 2011
Education
Universidad Autónoma de Guadalajara, Jalisco México, 2005
Internship
Carraway Methodist Medical Center, Birmingham, Alabama, 2008-2009
Residency
Carraway Methodist Medical Center, Birmingham, Alabama
Baptist Health System, Birmingham, Alabama, 2009
Fellowship
University of Alabama at Birmingham, 2012
State Licensure
Languages
English, Spanish
Publications by Dr. Navarro-Millan
Patient Education
Selected Books/Chapters
Navarro-Millán IY, Alarcón G S: "Lippincott's Primary Care Rheumatology." Book Chapter: "Overlap Syndromes and Unclassified or Undifferentiated Connective Tissue Disease" Lippincott, Williams & Wilkins. 2011: ISBN/ISSN: 9781609138080.
Selected Journal Articles
Sattui SE, Crow MK, Navarro-Millán I. The role of immunomodulatory medications in the treatment of COVID-19. Curr Opin Rheumatol. 2021 Sep 1;33(5):431-445. doi: 10.1097/BOR.0000000000000817. Review. PubMed PMID: 34397605; PubMed Central PMCID: PMC8373384.
Sattui SE, Rajan M, Lieber SB, Lui G, Sterling M, Curtis JR, Mandl LA, Navarro-Millán I. Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis. Semin Arthritis Rheum. 2021 Feb;51(1):292-298. doi: 10.1016/j.semarthrit.2020.09.022. Epub 2021 Jan 5. PubMed PMID: 33433365; PubMed Central PMCID: PMC8018291.
Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol. 2020 Dec;72(12):1990-1997. doi: 10.1002/art.41422. Epub 2020 Nov 4. PubMed PMID: 32602262; PubMed Central PMCID: PMC7361793.
Navarro-Millán I, Rajan M, Lui GE, Kern LM, Pinheiro LC, Safford MM, Sattui SE, Curtis JR. Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Semin Arthritis Rheum. 2020 Oct;50(5):988-995. doi: 10.1016/j.semarthrit.2020.07.008. Epub 2020 Jul 23. PubMed PMID: 32911290; PubMed Central PMCID: PMC8018290.
Navarro-Millán I, Young SR, Shurbaji S, McDavid C, Cornelius-Schecter A, Johnson B, Cherrington AL, Fraenkel L, Goodman SM, Curtis JR, Venkatachalam S, Safford MM. Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. BMC Rheumatol. 2020;4:26. doi: 10.1186/s41927-020-00123-w. eCollection 2020. PubMed PMID: 32514493; PubMed Central PMCID: PMC7265623.
Navarro-Millán I, Cornelius-Schecter A, O'Beirne RJ, Morris MS, Lui GE, Goodman SM, Cherrington AL, Fraenkel L, Curtis JR, Safford MM. Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis. BMC Rheumatol. 2020;4:14. doi: 10.1186/s41927-020-0112-5. eCollection 2020. PubMed PMID: 32159074; PubMed Central PMCID: PMC7057468.
Navarro-Millán I, Yang S, Chen L, Yun H, Jagpal A, Bartels CM, Fraenkel L, Safford MM, Curtis JR. Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1593-1599. doi: 10.1002/acr.23810. PubMed PMID: 30414353; PubMed Central PMCID: PMC6510643.
Selected Presentations
5/2012 6th National Young Research Investigator Forum, "American College of Rheumatology Annual Scientific Meeting, "Application of the New American College of Rheumatology/European League Against Rheumatism Rheumatoid Arthritis Remission Criteria in a United States Cohort" (Abstract Oral presentation) Destin, FL
9/2014 Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center (CAMAC) Research Day. "Association of Anti-Peptidyl Arginine Deiminase Antibodies with Radiographic Severity of Rheumatoid Arthritis in African Americans" (Abstract Oral Presentation) Birmingham, AL
4/2016 "Using Rheumatoid Arthritis Clinical Outcomes to Develop Patient Centered Research Questions" National Institutes of Health-National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) – Grand Rounds. Bethesda, Maryland
7/2016 "PROs in Rheumatoid Arthritis: Electronic Data Capture to Improve Patient Outcomes" Investigators Meeting –Rheumatology Research Foundation. Atlanta, GA
06/2019 “Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis” -ACR/EULAR Exchange Program Faculty, European League Against Rheumatism (EULAR) Annual Meeting, Madrid, Spain
04/2021 “The Rheumatoid Arthritis Example and Lessons for Psoriasis and Psoriatic Arthritis” - Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence to Practice Gap for Statins Stakeholders Meeting, NIH/NHLBI, Bethesda, MD
06/2021 “How to transform clinical patterns into research questions?” - Dr. Rafael González Alcover, Keynote Speaker, Puerto Rican Society of Rheumatologist (ARPR), San Juan, Puerto Rico
11/2021 “Addressing Health Disparities in Rheumatoid Arthritis” - American College of Rheumatology Annual Meeting. Convergence Virtual Meeting
Research
Industry Relationships
Industry Relationships
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of November 13, 2019, Dr. Navarro-Millan reported no relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.